Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated May 20, 2025, reports a transaction in the company's own shares. The filing covers share repurchase activity executed on May 19, 2025, pursuant to a non-discretionary agreement with Citigroup Global Markets Limited entered into on February 24, 2025.
Key Financial Metrics and Transaction Details
- Shares Purchased: 565,355 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 1,387.00 GBp; highest price paid was 1,402.50 GBp.
- Average Price: Volume-weighted average price paid was 1,394.81 GBp.
- Trading Venue: All transactions occurred on the London Stock Exchange (XLON).
- Treasury Holdings: Following this purchase, GSK holds 212,809,993 ordinary shares in treasury.
- Shares in Issue: 4,102,448,866 ordinary shares (excluding Treasury shares).
- Voting Rights: Total voting rights stand at 4,102,448,866.
Material Changes and Program Progress
Since the inception of the current buyback program on February 24, 2025, GSK has purchased an aggregate of 43,739,690 ordinary shares. The shares purchased in this specific transaction are being held as Treasury shares. The filing does not provide comparative financial data (revenue, profit, cash flow) as it is a transaction report rather than a periodic financial statement.
Guidance, Outlook, and Risks
The filing contains a standard cautionary statement regarding forward-looking statements. GSK notes that projections are subject to risks and uncertainties that may cause actual results to differ materially. Specific risk factors are referenced in the company's Annual Report on Form 20-F for 2024 and Q1 Results for 2025. No new guidance or management commentary regarding operational outlook is provided in this document.
Investor Verification Checklist
- Verify the total number of shares purchased under the buyback program since February 24, 2025 (43,739,690).
- Confirm the updated count of Treasury shares (212,809,993) and shares in issue (4,102,448,866) for voting rights calculations.
- Review the "Risk Factors" section in the 2024 Form 20-F and 2025 Q1 Results for context on forward-looking statements.
- Check the volume-weighted average price (1,394.81 GBp) against prevailing market rates on May 19, 2025.